Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Opioid free anesthesia is an anesthetic technique, in which administration of multimodal analgesia and sympathicolytics provides hemodynamic stability without use of opioids. Such management may be beneficial to the obese patients undergoing laparoscopic sleeve gastrectomy. Our study aims to compare opioid free anesthesia in such patients with standard, short-acting opioid based.
The study has been approved by Bioethical Committee of Medical University of Warsaw. Informed written consent will be obtained from all patients. Sample size of 60 patients has been calculated based on the Altman normogram to obtain 30% reduction of postoperative opioid consumption with significance and power of 90%.
Consenting patients scheduled for laparoscopic sleeve gastrectomy will be randomly assigned to the computer generated list to receive opioid free or standard opioid based anesthesia.
Opioid free protocol includes administration of dexmedetomidine, lidocaine, ketamine, magnesium sulphate whereas standard group will receive remifentanil TCI Minto Model.
After the end of operation all of the patient will receive oxycodone and additional doses via PCA system for postoperative analgesia.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Opioid liberal group | Active Comparator |
| |
| Opioid free group | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride [Dexdor] | Drug | Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation. |
| Measure | Description | Time Frame |
|---|---|---|
| Total postoperative oxycodone consumption | PCA (Patient's controlled analgesia) iv pump, oxycodone will be administered on patient's demand by 2mg boli, with lock out time 10 minutes | Day "0" |
| Postoperative pain score in NRS scale | NRS range from 0 for no pain to 10 for worst pain imaginable | Day "0", assessed 1 hour after operation |
| Postoperative pain score in NRS scale | NRS range from 0 for no pain to 10 for worst pain imaginable | Day "0", assessed 6 hours after operation |
| Postoperative pain score in NRS scale | NRS range from 0 for no pain to 10 for worst pain imaginable | Day "0", assessed 12 hours after operation |
| Postoperative pain score in NRS scale | NRS range from 0 for no pain to 10 for worst pain imaginable | Day "1" assessed 24 hours after operation |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative sedation score | 1-6 Ramsay sedation score; 1 - agitated or restless 6 - unresponsive | Day "0", assessed 1,6,12 and 24 hours after operation |
| Postoperative nausea and vomiting | Simplified PONV impact scale 0-6 0 - no nausea nor vomiting 6 - >3 episodes of vomiting and nausea all of the time |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Piotr Mieszczański, MD | Medical University of Warsaw | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Szpital Kliniczny Dzieciatka Jezus | Warsaw | 02-005 | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Remifentanil [Ultiva] | Drug | Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability. |
|
| Ketamine [Ketalar] | Drug | Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia. |
|
| Lidocaine [Xylocaine 2%] | Drug | Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation. |
|
| Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] | Drug | Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively. |
|
| Fentanyl [Fentanyl WZF] | Drug | Rescue dosis of 100 mcg iv will be administered if hypertension > 140/90 mmHg or tachycardia > 120min occurs. If necessary rescue dosis may be repeated. |
|
| Day "0", assessed 1,6,12 and 24 hours after operation |
| Rescue fentanyl administration dosis | In opioid free group, rescue fentanyl dosis will be administered if hypertension > 140/90 mmHg or tachycardia > 120/min occurs | intraoperative |
| Highest BP | Highest BP during operation | intraoperative |
| Lowest BP | Lowest BP during operation | intraoperative |
| Highest HR | Highest HR during operation | intraoperative |
| Lowest HR | Lowest HR during operation | intraoperative |
| Total ephedrine dosis | Ephedrine is a vasopressor used in case of hypotension to maintain mean arterial pressure > 65 mmHg or to increase blood pressure to check surgical hemostasis | intraoperative |
| Postoperative desaturation | SpO2 < 94% | Day "0", assessed 1,6,12 and 24 hours after operation |
| Patient's comfort assessed in QoR-40 formulary | QoR-40 scale is used to measure the quality of recovery after surgery and anesthesia, it is a 40 item questionnaire that provides a score across five dimensions: patient support, comfort, emotions, physical independence, and pain. Formulary will assess first 24 hours following the operation and will be filled by the patient 7 days after operation | 7 days postoperatively |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D010149 | Pain, Postoperative |
| D020250 | Postoperative Nausea and Vomiting |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D009325 | Nausea |
| D012817 | Signs and Symptoms, Digestive |
| D014839 | Vomiting |
Not provided
Not provided
| ID | Term |
|---|---|
| D020927 | Dexmedetomidine |
| D000077208 | Remifentanil |
| D007649 | Ketamine |
| D008012 | Lidocaine |
| D008278 | Magnesium Sulfate |
| D005283 | Fentanyl |
| ID | Term |
|---|---|
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011422 | Propionates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D017616 | Magnesium Compounds |
| D007287 | Inorganic Chemicals |
| D013431 | Sulfates |
| D013464 | Sulfuric Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |
Not provided
Not provided